Thomas Martin

TL;DR: OVA followed by auto-HCT is effective and safe for high-risk rrDLBCL and MRD testing in the relapsed setting was predictive of long-term survival.

TL;DR: From the binding studies, it is concluded that the isatuximab epitope on RBCs is masked in vitro and binding requires a certain CD38 conformation or co-factor, which may explain why interference is seen only in a subset of patients receiving isatUXimab when compared with interference seen in most patients on daratumumab therapy.

TL;DR: This is the first evidence of heterologous botA gene expression producing a soluble safe derivative of botulinum neurotoxin A needed as a molecular tool for exploratory research in neurosciences as well as a basis for raising protective immunity in humans.

TL;DR: In this paper , the anti-CD38 antibody isatuximab in combination with carfilzomib-dexamethasone (Isa-Kd) were evaluated in the randomized Phase 3 trial IKEMA (NCT03275285), in a prespecified, follow-up analysis of progression-free survival (PFS, primary study endpoint), final complete response (CR) using Hydrashift Isa immunofixation assay, minimal residual disease (MRD) negativity, and safety.